RARE logo

RARE Ultragenyx Pharmaceutical Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$16.48
-0.74 (-4.30%)

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody tha…

Market Cap: $1.68Bwww.ultragenyx.com

Price

No data yet.

Social Signal Score

43
5d
—
30d
48
10 mentions
—
60d
42
18 mentions
—
90d
40
30 mentions
—
news: 30

Analyst Ratings

34 analysts
Buyconsensus
Strong Buy 0Buy 21Hold 12Sell 1Strong Sell 0
Avg price target$25.54+55.0%
Low $16Median $23High $39
Current Consensus

Revenue

$173.00M+3459900.00%
$0.00$71.33M$142.67M$214.00M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-5.60
$-6.19–$-5.14
11 analysts
FY2026
$-1.41
$-2.12–$-0.56
11 analysts
FY2027
$0.11
$-0.29–$1.25
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Emil D. Kakkis
Sector
Healthcare
Industry
Biotechnology
Employees
1,371
Beta
0.32
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-5.65
www.ultragenyx.com